Long-Term Safety – Medxy AI

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

By MedXY 06/28/2026

The FOREST-HCM long-term study confirms aficamten's efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.

Diabetes & Endocrinology news

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

By MedXY 06/15/2026

Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.

Neurology news

Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study

By MedXY 10/23/2025

This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.

news OB/GYN & Women's Health Specialties

Long-Term Safety of Antenatal Corticosteroids: Insights from the 50-Year Follow-Up of the Auckland Steroid Trial

By MedXY 08/11/2025

The 50-year follow-up study on the Auckland Steroid Trial provides reassurance about the intergenerational safety of antenatal corticosteroid exposure concerning body mass index and various health outcomes in the second generation.